CoChat

TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma

Open access
Ge, Zhouhong, Zhou, Guoying, Campos Carrascosa, Lucia, Gausvik, Erik, Boor, Patrick P.C., Noordam, Lisanne, Doukas, Michael, Polak, Wojciech G., Terkivatan, Türkan, Pan, Qiuwei, Takkenberg, R. Bart, Verheij, Joanne, Erdmann, Joris I., IJzermans, Jan N.M., Peppelenbosch, Maikel P., Kraan, Jaco, Kwekkeboom, Jaap, Sprengers, Dave · 2021 · Cellular and Molecular Gastroenterology and Hepatology
Cited by 87

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background & Aims TIGIT is a co-inhibitory receptor, and its suitability as a target for cancer immunotherapy in HCC is unknown. PD1 blockade is clinically effective in about 20% of advanced HCC patients. Here we aim to determine whether co-blockade of TIGIT/PD1 has added value to restore functionality of HCC tumor-infiltrating T cells (TILs). Methods Mononuclear leukocytes were isolated from tumors, paired tumor-free liver tissues (TFL) and peripheral blood of HCC patients, and used for flow cytometric phenotyping and functional assays. CD3/CD28 T-cell stimulation and antigen-specific assays were used to study the ex vivo effects of TIGIT/PD1 single or dual blockade on T-cell functions. Results TIGIT was enriched, whereas its co-stimulatory counterpart CD226 was down-regulated on PD1 high CD8 + TILs. PD1 high TIGIT + CD8 + TILs co-expressed exhaustion markers TIM3 and LAG3 and demonstrated higher TOX expression. Furthermore, this subset showed decreased capacity to produce IFN-γ and TNF-α. Expression of TIGIT-ligand CD155 was up-regulated on tumor cells compared with hepatocytes in TFL. Whereas single PD1 blockade preferentially enhanced ex vivo functions of CD8 + TILs from tumors with PD1 high CD8 + TILs (high PD1 expressers), co-blockade of TIGIT and PD1 improved proliferation and cytokine production of CD8 + TILs from tumors enriched for PD1 int CD8 + TILs (low PD1 expressers). Importantly, ex vivo co-blockade of TIGIT/PD1 improved proliferation, cytokine production, and cytotoxicity of CD8 + TILs compared with single PD1 blockade. Conclusions Ex vivo , co-blockade of TIGIT/PD1 improves functionality of CD8 + TILs that do not respond to single PD1 blockade. Therefore co-blockade of TIGIT/PD1 could be a promising immune therapeutic strategy for HCC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcmgh.2021.03.003

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 87

Metadata

Authors
Ge, Z., Zhou, G., Campos Carrascosa, L., Gausvik, E., Boor, P. P. C., Noordam, L., Doukas, M., Polak, W. G., Terkivatan, T., Pan, Q., Takkenberg, R. B., Verheij, J., Erdmann, J. I., IJzermans, J. N. M., Peppelenbosch, M. P., Kraan, J., Kwekkeboom, J., & Sprengers, D.
Venue
Cellular and Molecular Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2021
Volume
12
Issue
2
Pages
443-464
ISSN
2352-345X (ISSN-L)
OpenAlex
W3141600657
Cited by
87
References
12
FWCI
4.81
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.